替吉奥联合顺铂与多西他赛联合顺铂治疗晚期食管癌的临床观察

Clinical Observation of S-1 Combined With Cisplatin or Docetaxel Combined With Cisplatin in Treatment of Advanced Esophageal Cancer

目的对晚期食管癌患者分别应用替吉奥+顺铂与多西他赛+顺铂进行治疗的临床效果展开观察与探究。方法以我院80例晚期食管癌患者为例,随机将其分为观察组与对照组,前者联合应用多西他赛与顺铂进行治疗,后者联合应用替吉奥与顺铂治疗。对比并评价两组的临床疗效。结果观察组患者的治疗总有效率与1年生存率分别为80.0%与65.0%,对照组分别为75.0%与60.0%,两组数据差异无统计学意义(P>0.05)。结论对于晚期食管癌患者,无论联合应用替吉奥与顺铂,还是应用多西他赛与顺铂进行化疗,均可获得较为显著的效果。

Objective To study the clinical effect of patients with advanced esophageal cancer were used S-1+cisplatin or docetaxel+cisplatin for the treatment.Methods80cases of advanced esophageal cancer in our hospital were taken as an example,and randomly divided into observation group and control group.The former was treated with docetaxel and cisplatin,the latter was treated with S-1and cisplatin in the treatment.The clinical efficacy of the two groups was compared and evaluated.Results The total effective rate and the1year survival rate of the observation group were80.00%and65.00%,respectively.The control group was75.00%and60.00%,respectively.The difference between the two groups was not statistically significant(P>0.05).Conclusion For patients with advanced esophageal cancer,whether combined with cisplatin or s-1,or docetaxel and cisplatin chemotherapy,can achieve more significant results.